Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)
Quetiapine drug, mood stabilizer · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood) | DRUG | - |
Inclusion Criteria: * Patients with a diagnosis of bipolar I disorder or bipolar II disorder, currently depressed, aged 18 to 65 years old and outpatient status at enrolment and randomization. Exclusion Criteria: * Patients with a current DSM-IV Axis I disorder other than bipolar disorder that is...
Top 10 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 4 | PHASE3 | Xanomeline and trospium chloride, Xanomeline/Trospium Chloride |
| AbbVie, Inc. | ABBV | 3 | PHASE3 | Cariprazine, ABBV-932, Icalcaprant |
| Xenon Pharmaceuticals Inc. | XENE | 2 | PHASE3 | Azetukalner |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Rapport Therapeutics, Inc. | RAPP | 1 | PHASE2 | RAP-219 |
| Neurocrine Biosciences, Inc. | NBIX | 1 | PHASE2 | NBI-1117568 |
| Alto Neuroscience, Inc. | ANRO | 1 | PHASE2 | ALTO-100 |
| LB Pharmaceuticals, Inc. | LBRX | 1 | PHASE2 | LB-102 |
| BioXcel Therapeutics, Inc. | BTAI | 1 | PHASE1 | BXCL501 |
| Alzamend Neuro, Inc. | ALZN | 1 | PHASE1 | AL001 |
Quetiapine is used for bipolar disorder, including bipolar depression. It is a small molecule in the psychiatry therapeutic area developed by AstraZeneca PLC under the ticker AZN. The Phase 3 trial NCT00206141 studied Seroquel in bipolar depression versus lithium in 672 participants.
Quetiapine targets HTR2A, DRD2, and HTR2C as an antagonist. By blocking these receptors, it is designed to modulate serotonin and dopamine signaling in the brain, which is the basis for its use in bipolar disorder.
Quetiapine is developed by AstraZeneca PLC, which trades under the ticker AZN. The company is responsible for the drug's clinical development in bipolar disorder.
Quetiapine is in Phase 3 development for bipolar disorder. The completed Phase 3 trial NCT00206141 evaluated Seroquel in bipolar depression versus lithium and enrolled 672 participants. It is an investigational small molecule and has not been approved for this use based on the available information.
Quetiapine has been studied in the completed Phase 3 trial NCT00206141, titled Seroquel in Bipolar Depression Versus Lithium. The trial enrolled 672 participants across multiple countries, including Canada, Germany, and South Korea, and included adults 18 years and older.
Yes, quetiapine is also known as quetiapine fumarate and by the brand name Seroquel. These names refer to the same small molecule developed by AstraZeneca PLC for bipolar disorder.